CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Paratek Announces Appointment of Minnie Baylor-Henry to its Board of Directors

Life Sciences Review Life Sciences Review | Tuesday, June 22, 2021
Tweet

Paratek focuses on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use.


FREMONT, CA: Paratek Pharmaceuticals, a commercial-stage biopharmaceutical company recently appointed Minnie Baylor-Henry, J.D., a recognized leader in the area of food and drug laws and regulations to the company’s Board of Directors. The firm focuses on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use.


“We are delighted to welcome Minnie to Paratek’s Board of Directors,” said Michael Bigham, Chairman of the Board, Paratek. “She brings extensive expertise and unique perspectives from her work with top global businesses, government agencies and leading non-profit organizations that will be invaluable as we continue to pursue life cycle initiatives for NUZYRA and continue our commitment to supporting the fight against antimicrobial resistance.”


Minnie is the president of B-Henry & Associates, a consulting firm that helps life sciences companies with regulatory and compliance strategies. Minnie previously worked for Johnson & Johnson (J&J), most recently as Worldwide Vice-President for Regulatory Affairs for J&J’s Medical Devices & Diagnostics business, and at Deloitte & Touche as a National Director for Regulatory & Capital Markets Consulting. Minnie began her career at J&J after working for the U.S. Food and Drug Administration (FDA).


 


“Paratek has established NUZYRA as one of the most successful antibiotics launched in the last five years and I look forward to helping guide the company through its next phase of growth and development,” commented Minnie. “It is an exciting time to join the Board given the recent expansion of NUZYRA into the community setting, the companys ongoing research into NUZYRAs potential against biothreat pathogens including anthrax and their plans to start a Phase 2b study exploring NUZYRA as a possible treatment for Non-Tuberculous Mycobacteria (NTM) infections.”


She previously served as the Board Chair for the Food and Drug Law Institute (FDLI). She also served as President and Chair of the Board of Directors for the Drug Information Association (DIA), where she is now a Fellow. Minnie is the Chair of the Board of Visitors at Howard University’s College of Pharmacy and a Trustee for Howard University. She also serves on the boards of scPharmaceuticals, Apyx Medical, and PolarityTE, all of which are publicly traded companies. Flame Biosciences, a clinical-stage biopharmaceutical startup, has appointed her as an Independent Director. In addition, Minnie sits on the boards of various non-profit organizations, including The Partnership, Mass Eye and Ear Hospital, and Dress for Success Boston. She earned her bachelor’s degree in pharmacy from Howard University and her law degree from Catholic University’s Columbus School of Law.


Weekly Brief

loading
Top 10 Preeminent Cros – 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

The Importance of Technology in Multinational Clinical Research

Hepion Pharmaceuticals to Get a Total of $ 3.2 Million in Non-Dilutive Financing

Benefits that Medical Writing Offers

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/paratek-announces-appointment-of-minnie-baylorhenry-to-its-board-of-directors-nwid-413.html